Rare Diseases
Immunoglobulin G4 (IgG4) Related Disease
Testing new treatments for people with IgG4 related disease (fibro-inflammatory condition).
Research Objectives
Status
Completed
Recruitment
Closed
Patient Group
Adults aged ≥ 18 years who have recently active IgG4-RD (initial diagnosis or flare) that requires new or ongoing treatment, are at high risk of future flare, and meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) IgG4-RD classification criteria.
Total Participants
2
Study location
The Wesley Hospital
Study type
Industry Sponsored
Sponsors: Viela Bio
Lead investigators
- Dr Daman Langguth
Clinical Trial Coordinator
- Venita Bali
Technical title
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in Immunoglobulin G4-related disease (IgG4) Related Disease (MITIGATE)
About this research project
There are currently no medicinal products approved for the treatment of IgG4-RD. The majority of cases follow a relapsing course that can lead to permanent tissue damage with potential morbidity and mortality. This project aims to develop an effective product.
The purpose of this study is to better understand the safety and side effects of Inebilizumab and to find out if it helps people with IgG4 related disease.
Latest News
Mitsubishi Development announces largest Australian partnership
On Thursday 6 July Wesley Research Institute and Mitsubishi Development signed a new partnership, the largest for Mitsubishi Development in Australia, which will provide significant funding for Navicare over the next two years.
Maureen Stevenson Award
Maureen Stevenson received the 2023 Community Philanthropist of the Year Award at the Queensland Philanthropy Awards (QCF) held at Brisbane Town Hall.
Australian scientists prove medicinal cannabis can be a lifechanging treatment for people with Tourette Syndrome
Imagine the pain and embarrassment of violent movements and uncontrollable outbursts at school or work…that’s what life was like for Chris Wright (35) before he started a ground-breaking clinical trial of medicinal cannabis.